8.39
-0.03
(-0.36%)
Real-time:
11:14AM EDT
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 8.13 - 8.43 |
| 52 week | 1.98 - 13.18 |
| Open | 8.25 |
| Vol / Avg. | 5,256.00/75,157.00 |
| Mkt cap | 125.98M |
| P/E | - |
| Div/yield | - |
| EPS | -2.80 |
| Shares | 15.02M |
| Beta | 2.34 |
| Inst. own | 47% |
Events
Apr 30, 2013
MEI Pharma Inc at Needham Healthcare Conference
Mar 26, 2013
MEI Pharma Annual Meeting of Stockholders
Mar 19, 2013
MEI Pharma Inc at Roth Conference
Mar 6, 2013
MEI Pharma Inc at Cowen Health Care Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -69.17% | -142.74% |
| Return on average equity | -77.49% | -235.35% |
| Employees | 10 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 101, 11975 El Camino Real
SAN DIEGO, CA 92130
United States - Map
+1-858-7926300 (Phone)
+1-302-6555049 (Fax)
SAN DIEGO, CA 92130
United States - Map
+1-858-7926300 (Phone)
+1-302-6555049 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
MEI Pharma, Inc., formerly Marshall Edwards, Inc., is a development-stage oncology company. The Company is engaged in the development of drugs for the treatment of cancer. The Company focuses on the clinical development of therapeutics targeting cancer metabolism. The Company is a wholly owned subsidiary of Novogen Limited (Novogen). As of September 26, 2011, Novogen owned approximately 51.5% interests in the Company. The Company's has two geographic segments: the United States and Australia. The Company has two clinical product development programs, which include NADH Oxidase Inhibitors and Mitochondrial Inhibitors. NADH Oxidase Inhibitors includes Phenoxodiol and ME-143. Mitochondrial Inhibitors includes NV-128 and ME-344. Marshall Edwards Pty Ltd. is a wholly owned subsidiary of the Company. In February 2013, Novogen Limited completed its exchanged offer through which it was to split off its 63.5% interest in the Company.
Officers and directors
| Daniel P. Gold Ph.D. | President, Chief Executive Officer, Director | |
| Thomas M. Zech | Chief Financial Officer | |
| Robert D. Mass M.D. | Chief Medical Officer | |
| Christine A. White M.D. | Lead Independent Director | |
| Charles V. Baltic III | Independent Director | |
| Leah Rush Cann | Independent Director | |
| Thomas C. Reynolds M.D., Ph.D. | Independent Director | |
| William D. Rueckert B.A. | Independent Director |